Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphetamine
Drug ID BADD_D00130
Description Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 and first synthesized by 1927. After being proven to reduce drug-induced anesthesia and produce arousal and insomnia, amphetamine racemic mix was registered by Smith, Kline and French in 1935. Amphetamine structure presents one chiral center and it exists in the form of dextro- and levo-isomers.[A18540] The first product of Smith, Kline and French was approved by the FDA on 1976.[L5194] During World War II, amphetamine was used to promote wakefulness in the soldiers. This use derived into a large overproduction of amphetamine and all the surplus after the war finalized ended up in the black market, producing the initiation of the illicit abuse.[A18540]
Indications and Usage Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540] ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271] On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274] Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283]
Marketing Status approved; illicit; investigational
ATC Code N06BA01
DrugBank ID DB00182
KEGG ID D07445
MeSH ID D000661
PubChem ID 3007
TTD Drug ID D05BMG
NDC Product Code 70165-005; 24478-110; 69238-1564; 69452-228; 70165-030; 70165-015; 24478-109; 24478-102; 24478-108; 27808-102; 70165-020; 70165-025; 69238-1563; 69452-227; 70165-010; 24478-106
UNII CK833KGX7E
Synonyms Amphetamine | Amfetamine | Phenopromin | Desoxynorephedrin | Phenamine | Centramina | Fenamine | Mydrial | Thyramine | Amphetamine Sulfate | Sulfate, Amphetamine | Amphetamine Sulfate (2:1) | l-Amphetamine | l Amphetamine | levo-Amphetamine | levo Amphetamine | Levoamphetamine
Chemical Information
Molecular Formula C9H13N
CAS Registry Number 300-62-9
SMILES CC(CC1=CC=CC=C1)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urticaria23.04.02.001; 10.01.06.0010.000586%
Vasoconstriction24.04.03.008; 23.06.05.0070.000177%Not Available
Ventricular fibrillation02.03.04.0080.000120%
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Intracardiac thrombus02.11.01.017; 24.01.05.0030.000080%Not Available
Coronary artery dissection12.02.01.035; 24.02.02.001; 02.02.01.0040.000321%Not Available
Tooth infection11.01.04.004; 07.09.01.004--
Quadriparesis17.01.04.0120.000080%Not Available
Left ventricular dysfunction02.04.02.0110.000120%
Spinal epidural haematoma24.07.04.020; 17.08.01.038; 12.01.13.0060.000161%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Affect lability19.04.01.001--Not Available
Dysphemia19.19.03.005; 17.02.08.010--Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.000080%
Disturbance in sexual arousal19.08.04.003--Not Available
Libido disorder19.08.03.004; 21.03.02.006--Not Available
Abnormal behaviour19.01.01.0010.001445%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Psychotic disorder19.03.01.002--
Pulmonary arterial hypertension22.06.01.002; 24.08.03.0030.000080%Not Available
Dermatillomania23.03.11.011; 19.06.05.005--Not Available
Acute kidney injury20.01.03.0160.000321%
Hypoxic-ischaemic encephalopathy17.13.02.006; 24.04.06.021; 22.02.02.0110.000080%Not Available
Reversible cerebral vasoconstriction syndrome24.04.06.026; 18.06.01.004; 17.08.02.0140.000080%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000161%
Carotid artery dissection24.02.04.004; 17.08.06.0030.000161%Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages